KDM1A promotes thyroid cancer progression and maintains stemness through the Wnt/β-catenin signaling pathway

Wei Zhang(Union Hospital), Xianhui Ruan(Tianjin Medical University Cancer Institute and Hospital), Yaoshuang Li(Nankai University), Jingtai Zhi(Tianjin First Center Hospital), Linfei Hu(Tianjin Medical University Cancer Institute and Hospital), Xiukun Hou(Tianjin Medical University Cancer Institute and Hospital), Xianle Shi(Columbia University Irving Medical Center), Xin Wang(Tianjin Medical University Cancer Institute and Hospital), Jinpeng Wang(Tianjin Medical University Cancer Institute and Hospital), Weike Ma(Tianjin Medical University Cancer Institute and Hospital), Pengfei Gu(Tianjin Medical University Cancer Institute and Hospital), Xiangqian Zheng(Tianjin Medical University Cancer Institute and Hospital), Ming Gao(Tianjin Medical University Cancer Institute and Hospital)
Theranostics
January 1, 2022
10.7150/thno.66142
Cited by 114Open Access
Full Text

Abstract

Background: Cancer stem cells (CSCs) are highly tumorigenic, chemotherapy-resistant, tumor growth-sustaining, and are implicated in tumor recurrence. Previous studies have shown that lysine-specific histone demethylase 1A (KDM1A) is highly expressed in several human malignancies and CSCs. However, the role of KDM1A in CSCs and the therapeutic potential of KDM1A inhibitors for the treatment of the advanced thyroid cancer are poorly understood. Methods: Firstly, KDM1A was identified as an important epigenetic modifier that maintained the stemness of thyroid cancer through a mini histone methylation modifier screen and confirmed in thyroid cancer tissues and cell lines. RNA sequence was performed to discover the downstream genes of KDM1A. The underlying mechanisms were further investigated by ChIP, IP and dual luciferase reporter assays, gain and loss of function assays.

Related Papers

No related papers found

Powered by citation graph analysis